Findings

What do systematic reviews say?

22 questions · 22 findings · 8 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 31.8%GRADE not reported 0 · 0%Very low 7 · 31.8%Low 4 · 18.2%Moderate 4 · 18.2%High 0 · 0%

Summary of findings: acrylic vs silicone punctal plugs

Adverse events · mostly women with dry eye syndrome

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Summary of findings table ‐ Collagen vs silicone punctal plugs

Adverse events · adults with dry eye syndrome

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Summary of findings for NSAIDs vs corticosteroids

Adverse events · people who received phacoemulsification

The review found no eligible studies for this question.

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: punctal plugs vs cyclosporine A

Adverse events · adults with dry eye syndrome

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings: punctal plugs vs pilocarpine

Adverse events · adults with dry eye syndrome

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Summary of findings: punctal plugs vs no punctal plugs

Adverse events · adults with dry eye syndrome

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 146 participants
Very low

Rituximab vs intravenous methylprednisolone

Adverse events · thyroid‐associated ophthalmopathy

Summary of findings table ‐ Rituximab showed no clear difference in adverse events compared with intravenous methylprednisolone (low certainty).

1 finding from 1 review

Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
RR 1.39 [0.9, 2.13]
1 study · 31 participants
Low

Summary of findings: intracanalicular vs silicone punctal plugs

Adverse events · adults with dry eye syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: autologous serum vs Normal saline

Adverse events · people with dry eye

The review found no eligible studies for this question.

1 finding from 1 review

Autologous serum eye drops for dry eye 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: autologous serum vs artificial tears

Adverse events · people with dry eye

The review found no eligible studies for this question.

1 finding from 1 review

Autologous serum eye drops for dry eye 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Pseudophakia vs aphakia

Adverse events · children younger than two years of age with bilateral congenital cataracts

1 finding from 1 review

Surgical interventions for bilateral congenital cataract in children aged two years and under 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Summary of findings: punctal plugs in the upper vs lower puncta

Adverse events · adults with dry eye syndrome

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Summary of findings for NSAIDs plus corticosteroids vs corticosteroids

Adverse events · people who received phacoemulsification

The review found no eligible studies for this question.

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: bevacizumab vs ranibizumab

Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.51 [0.05, 5.62]
1670 participants
Moderate

Summary of findings: bevacizumab vs ranibizumab

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 1.15 [0.99, 1.34]
6 studies · 3365 participants
Moderate

Summary of findings: punctal plugs vs artificial tears

Adverse events (punctate epithelial keratopathy) · adults with dry eye syndrome

Summary of findings: punctal plugs showed no clear difference in adverse events (punctate epithelial keratopathy) compared with artificial tears (low certainty).

1 finding from 1 review

Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
RR 1.33 [0.57, 3.12]
Studies not reported
Low

Anti‐VEGF vs control

Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.52 [0.03, 8.25]
6 studies · 2667 participants
Moderate

Anti‐VEGF vs control

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.17 [0.01, 4.24]
6 studies · 2667 participants
Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Systemic adverse events at · adults with centre‐involving diabetic macular oedema

Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
Peto OR 1.32 [0.61, 2.86]
Studies not reported
Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

Systemic adverse events at · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found